CD8A and infection: These findings may help to explain why current SARS-CoV-2 vaccines protect against severe disease following infection with SARS-CoV-2 variants such as Omicron but also highlight the importance of developing vaccines that are able to activate CD4+ and CD8+ T cell responses in addition to NAb (Ferguson et al., 2021).